[Warm autoimmune hemolytic anemia and IgM-monoclonal gammopathy following BNT162b2 COVID-19 vaccine in a patient with splenic marginal zone lymphoma].
Rinsho Ketsueki
; 63(10): 1379-1385, 2022.
Article
in Japanese
| MEDLINE | ID: covidwho-2110946
ABSTRACT
There is currently no evidence that a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine might be associated with the development of autoimmune hemolytic anemia or disease progression in patients with mature B-cell neoplasm. Our patient was a 71-year-old man with indolent mature B-cell neoplasm who had been monitored for many years without treatment. After receiving the second dose of the BNT162b2 mRNA COVID-19 vaccine, he developed severe warm autoimmune hemolytic anemia. Although steroid therapy improved his anemia, he continued to develop IgM-monoclonal gammopathy, renal insufficiency, and splenomegaly. He was diagnosed with splenic marginal zone lymphoma after undergoing splenectomy. The splenectomy improved the patient's symptoms. We assessed his SARS-CoV-2 specific antibody response, but the patient's serologic response to the vaccine was impaired. In patients with mature B-cell neoplasm, a non-specific immune response after vaccination might be associated with paraneoplastic syndromes.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Paraproteinemias
/
Splenic Neoplasms
/
Leukemia, Lymphocytic, Chronic, B-Cell
/
Lymphoma, B-Cell
/
COVID-19 Vaccines
/
COVID-19
/
Anemia, Hemolytic, Autoimmune
Type of study:
Case report
Topics:
Long Covid
/
Vaccines
Limits:
Aged
/
Humans
/
Male
Language:
Japanese
Journal:
Rinsho Ketsueki
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS